{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:55:30Z","timestamp":1765727730142},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s10067-010-1630-0","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T04:28:50Z","timestamp":1291091330000},"page":"87-97","source":"Crossref","is-referenced-by-count":40,"title":["B cell depletion for autoimmune diseases in paediatric patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Annette F.","family":"Jansson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmin","family":"Kuemmerle-Deschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Gruhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Birgitta","family":"Kranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartwig","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Kleinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Pape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann J.","family":"Girschick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes P.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Moebius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Peitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veit","family":"Grote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,1]]},"reference":[{"key":"1630_CR1","first-page":"1245","volume":"35","author":"PJ Mease","year":"2008","unstructured":"Mease PJ (2008) B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 35:1245\u20131255","journal-title":"J Rheumatol"},{"key":"1630_CR2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"BD Cheson","year":"2008","unstructured":"Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359:613\u2013626","journal-title":"N Engl J Med"},{"key":"1630_CR3","doi-asserted-by":"crossref","unstructured":"Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A (2007) Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma. Cochrane Database Syst Rev (4):CD003805","DOI":"10.1002\/14651858.CD003805.pub2"},{"key":"1630_CR4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2007.085787","volume":"68","author":"E Keystone","year":"2009","unstructured":"Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets MW, Shaw T (2009) Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68:216\u2013221","journal-title":"Ann Rheum Dis"},{"key":"1630_CR5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpeds.2006.12.038","volume":"150","author":"LB Giulino","year":"2007","unstructured":"Giulino LB, Bussel JB, Neufeld EJ (2007) Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr 150:338\u2013344","journal-title":"J Pediatr"},{"key":"1630_CR6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676\u2013688","journal-title":"N Engl J Med"},{"key":"1630_CR7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/adc.2007.126276","volume":"93","author":"A Podolskaya","year":"2008","unstructured":"Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K (2008) B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 93:401\u2013406","journal-title":"Arch Dis Child"},{"key":"1630_CR8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00467-007-0694-9","volume":"23","author":"O Nwobi","year":"2008","unstructured":"Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G (2008) Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 23:413\u2013419","journal-title":"Pediatr Nephrol"},{"key":"1630_CR9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pediatrneurol.2008.05.015","volume":"39","author":"WG Leen","year":"2008","unstructured":"Leen WG, Weemaes CM, Verbeek MM, Willemsen MA, Rotteveel JJ (2008) Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. Pediatr Neurol 39:213\u2013217","journal-title":"Pediatr Neurol"},{"key":"1630_CR10","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269\u20131279","journal-title":"Pediatr Nephrol"},{"key":"1630_CR11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejpn.2006.10.005","volume":"11","author":"L Titomanlio","year":"2007","unstructured":"Titomanlio L, Soyah N, Guerin V, Delanoe C, Sterkers G, Evrard P, Husson I (2007) Rituximab in subacute sclerosing panencephalitis. Eur J Paediatr Neurol 11:43\u201345","journal-title":"Eur J Paediatr Neurol"},{"key":"1630_CR12","first-page":"335","volume":"80","author":"AJ Mamelak","year":"2007","unstructured":"Mamelak AJ, Eid MP, Cohen BA, Anhalt GJ (2007) Rituximab therapy in severe juvenile pemphigus vulgaris. Cutis 80:335\u2013340","journal-title":"Cutis"},{"key":"1630_CR13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/pbc.21166","volume":"49","author":"M Franchini","year":"2007","unstructured":"Franchini M, Zaffanello M, Veneri D, Lippi G (2007) Rituximab for the treatment of childhood chronic idiopathic thrombocytopenic purpura and hemophilia with inhibitors. Pediatr Blood Cancer 49:6\u201310","journal-title":"Pediatr Blood Cancer"},{"key":"1630_CR14","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.22856","volume":"56","author":"MA Cooper","year":"2007","unstructured":"Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ (2007) Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 56:3107\u20133111","journal-title":"Arthritis Rheum"},{"key":"1630_CR15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/RHU.0b013e3181886064","volume":"14","author":"AM Patel","year":"2008","unstructured":"Patel AM, Lehman TJ (2008) Rituximab for severe refractory pediatric Wegener granulomatosis. J Clin Rheumatol 14:278\u2013280","journal-title":"J Clin Rheumatol"},{"key":"1630_CR16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456\u2013473","journal-title":"Cancer Treat Rev"},{"key":"1630_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00431-006-0217-x","volume":"166","author":"AF Jansson","year":"2007","unstructured":"Jansson AF, Wintergerst U, Renner ED, Belohradsky BH (2007) Rituximab-induced long-term remission in two children with SLE. Eur J Pediatr 166:177\u2013181","journal-title":"Eur J Pediatr"},{"key":"1630_CR18","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1097\/TP.0b013e318188ac0c","volume":"86","author":"V Guerin","year":"2008","unstructured":"Guerin V, Yakouben K, Lescoeur B, Pedron B, Dalle JH, Baruchel A, Sterkers G (2008) Prolonged agammaglobulinemia despite unaltered B-cell lymphopoiesis after peritransplant-rituximab administration in a child. Transplantation 86:1322\u20131323","journal-title":"Transplantation"},{"key":"1630_CR19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1532\/IJH97.E0518","volume":"84","author":"E Parodi","year":"2006","unstructured":"Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghia U (2006) Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol 84:48\u201353","journal-title":"Int J Hematol"},{"key":"1630_CR20","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/art.21351","volume":"52","author":"SD Marks","year":"2005","unstructured":"Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168\u20133174","journal-title":"Arthritis Rheum"},{"key":"1630_CR21","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","volume":"107","author":"CM Bennett","year":"2006","unstructured":"Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ (2006) Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107:2639\u20132642","journal-title":"Blood"},{"key":"1630_CR22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2006.01.041","volume":"148","author":"M Willems","year":"2006","unstructured":"Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, Deschenes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623\u2013627","journal-title":"J Pediatr"},{"key":"1630_CR23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpeds.2006.10.067","volume":"150","author":"M El-Hallak","year":"2007","unstructured":"El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP (2007) Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 150:376\u2013382","journal-title":"J Pediatr"},{"key":"1630_CR24","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390\u20131400","journal-title":"Arthritis Rheum"},{"key":"1630_CR25","unstructured":"Klein A, Cimaz R, Azoulay E, Baudouin V, Descloux E, Belot A, Hubert P, Quartier P, Decramer S, Niaudet P, Bader-Meunier B (2007) Early mortality in childhood onset systemic lupus erythematosus (SLE). Arthritis Rheum 56(Suppl.):S880"},{"key":"1630_CR26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","volume":"149","author":"N Cooper","year":"2010","unstructured":"Cooper N, Arnold DM (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 149:3\u201313","journal-title":"Br J Haematol"},{"key":"1630_CR27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0028-1109782","volume":"48","author":"MA Stange","year":"2010","unstructured":"Stange MA, Tutarel O, Pischke S, Schneider A, Strassburg CP, Becker T, Barg-Hock H, Basturk M, Wursthorn K, Cornberg M, Ott M, Greten TF, Manns MP, Wedemeyer H (2010) Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. Z Gastroenterol 48:258\u2013263","journal-title":"Z Gastroenterol"},{"key":"1630_CR28","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM200109273451315","volume":"345","author":"F Suzan","year":"2001","unstructured":"Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000","journal-title":"N Engl J Med"},{"key":"1630_CR29","first-page":"894","volume":"85","author":"A Bermudez","year":"2000","unstructured":"Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A (2000) Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85:894\u2013895","journal-title":"Haematologica"},{"key":"1630_CR30","unstructured":"FDA (US Food and Drug Administration) (2009) Rituxan (rituximab)\u2014PML. Available at http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm187791.htm . Accessed 1 December 2009"},{"key":"1630_CR31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1704307","volume":"33","author":"S Imashuku","year":"2004","unstructured":"Imashuku S, Teramura T, Morimoto A, Naya M, Kuroda H (2004) Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant 33:129\u2013130","journal-title":"Bone Marrow Transplant"},{"key":"1630_CR32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10428190701742506","volume":"49","author":"SH Lim","year":"2008","unstructured":"Lim SH, Esler WV, Zhang Y, Zhang J, Periman PO, Burris C, Townsend M (2008) B-cell depletion for 2\u00a0years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 49:152\u2013153","journal-title":"Leuk Lymphoma"},{"key":"1630_CR33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0609.2006.00693.x","volume":"77","author":"M Nishio","year":"2006","unstructured":"Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, Kumano K, Minauchi K, Yamaguchi K, Takeda Y, Sato N, Koizumi K, Mukai M, Koike T (2006) Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol 77:226\u2013232","journal-title":"Eur J Haematol"},{"key":"1630_CR34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/07357900701809068","volume":"26","author":"AR Walker","year":"2008","unstructured":"Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, Friedberg JW (2008) Profound hypogammaglobulinemia 7\u00a0years after treatment for indolent lymphoma. Cancer Invest 26:431\u2013433","journal-title":"Cancer Invest"},{"key":"1630_CR35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.23171","volume":"58","author":"RJ Looney","year":"2008","unstructured":"Looney RJ, Srinivasan R, Calabrese LH (2008) The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 58:5\u201314","journal-title":"Arthritis Rheum"},{"key":"1630_CR36","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","volume":"358","author":"P Quartier","year":"2001","unstructured":"Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511\u20131513","journal-title":"Lancet"},{"key":"1630_CR37","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.berh.2006.05.010","volume":"20","author":"JC Edwards","year":"2006","unstructured":"Edwards JC, Cambridge G, Leandro MJ (2006) B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 20:915\u2013928","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1630_CR38","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56:3896\u20133908","journal-title":"Arthritis Rheum"},{"key":"1630_CR39","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/art.22967","volume":"56","author":"YK Teng","year":"2007","unstructured":"Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM (2007) Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 56:3909\u20133918","journal-title":"Arthritis Rheum"},{"key":"1630_CR40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","volume":"146","author":"N Cooper","year":"2009","unstructured":"Cooper N, Davies EG, Thrasher AJ (2009) Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 146:120\u2013122","journal-title":"Br J Haematol"},{"key":"1630_CR41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/jcp.2009.068940","volume":"63","author":"L Diwakar","year":"2010","unstructured":"Diwakar L, Gorrie S, Richter A, Chapman O, Dhillon P, Al-Ghanmi F, Noorani S, Krishna MT, Huissoon A (2010) Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 63:275\u2013277","journal-title":"J Clin Pathol"},{"key":"1630_CR42","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","volume":"74","author":"A Pestronk","year":"2003","unstructured":"Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74:485\u2013489","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1630_CR43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","volume":"25","author":"SP Treon","year":"2002","unstructured":"Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KC (2002) CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 25:72\u201381","journal-title":"J Immunother"},{"key":"1630_CR44","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12185-010-0528-6","volume":"91","author":"E Irie","year":"2010","unstructured":"Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, Kameoka J, Harigae H, Ishii T (2010) Severe hypogammaglobulinemia persisting for 6\u00a0years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 91:501\u2013508","journal-title":"Int J Hematol"},{"key":"1630_CR45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","volume":"117","author":"R Eisenberg","year":"2005","unstructured":"Eisenberg R, Looney RJ (2005) The therapeutic potential of anti-CD20 \u201cwhat do B-cells do?\u201d. Clin Immunol 117:207\u2013213","journal-title":"Clin Immunol"},{"key":"1630_CR46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-0609.2008.01174.x","volume":"82","author":"M Nishio","year":"2009","unstructured":"Nishio M, Endo T, Fujimoto K, Yamamoto S, Obara M, Yamaguchi K, Takeda Y, Goto H, Kasahara I, Sato N, Koike T (2009) FCGR3A-158V\/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol 82:143\u2013147","journal-title":"Eur J Haematol"},{"key":"1630_CR47","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/ard.2008.091124","volume":"67","author":"TY Lu","year":"2008","unstructured":"Lu TY, Jonsdottir T, van Vollenhoven RF, Isenberg DA (2008) Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases. Ann Rheum Dis 67:1493\u20131494","journal-title":"Ann Rheum Dis"},{"key":"1630_CR48","first-page":"379","volume":"144","author":"S Leuci","year":"2009","unstructured":"Leuci S, Levine D, Zhang J, Razzaque Ahmed A (2009) Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells. G Ital Dermatol Venereol 144:379\u2013409","journal-title":"G Ital Dermatol Venereol"},{"key":"1630_CR49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii\/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222\u2013233","journal-title":"Arthritis Rheum"},{"key":"1630_CR50","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MPH.0b013e3181cf0726","volume":"32","author":"MR Pranzatelli","year":"2010","unstructured":"Pranzatelli MR, Tate ED, Verhulst SJ, Bertolone SJ, Bhatla D, Granger M, Lebowizc J, Lockhart SK, Wiley JM (2010) Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 32:e167\u2013e172","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1630-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1630-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:51:46Z","timestamp":1559105506000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1630-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1630-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,1]]}}}